**National Center for Emerging and Zoonotic Infectious Diseases** 

## Late-Onset Sepsis/Meningitis Event

LaTasha R. Boswell RN, BSN, MPH, CIC

**Infection Prevention Consultant** 

CACI, Subcontractor to Leidos | Contractor for the National Healthcare Safety Network (NHSN)

NCEZID, Division of Healthcare Quality Promotion (DHQP)

**Centers for Disease Control and Prevention (CDC)** 

nhsn@cdc.gov

## **Objectives**

- Locate LOS/MEN resources for reporting and education
- Define the National Healthcare Safety Network (NHSN) criteria for LOS/MEN
- Identify the data requirements for electronic detection and reporting of LOS/MEN numerator and denominator data



### Neonatal Component

Use the Neonatal Component to track healthcare-associated infections and events in very low birth extremely premature neonates housed in acute care hospital facilities.

### Facilities Reporting in Neonatal Component

Acute Care Hospitals

### New Users

 <u>Enroll New Facility</u> Neonatal Component

> Website Live!!!

Neonatal Training

### Neonatal Modules & Events

Access relevant training, protocols, data collection forms and supporting materials for each module.

LOS/MEN Events

https://www.cdc.gov/nhsn/neonatal/index.html

## Late-Onset Sepsis/Meningitis Protocol



### https://www.cdc.gov/nhsn/neonatal/los-men/index.html

NATIONAL HEALTHCARE

January 2022

#### Late Onset Sepsis / Meningitis Event

#### Table of Contents

ate Onset Sepsis / Meningitis Event	
troduction:	
etails:	
efinitions:	
able 1: Examples of Infants Eligible for Surveillance Once Admitted to the Facility	5
igure 1. Decision Flow to Determine Eligible Infants for the LOS/MEN Denominator	6
able 2. Examples of Patient Transfer within the Transfer Rule Timeframe	7
able 3. Neonatal Laboratory-Confirmed Bloodstream Infection Criteria	9
able 4. Neonatal Laboratory-Confirmed Meningitis Criteria	
able 5. Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period	
able 6. List of Intravenous Antimicrobials Eligible to Cite an NLCBI 2 or NLCM 2 Event	
igure 2. Guidance for Determining LOS and MEN Events	
ata Analysis:	
ppendix A – CDC Location Label	
eferences	

#### Introduction:

Late onset sepsis (LOS) and Meningitis (MEN) are common complications of extreme prematurity. Studies have indicated that 36% of extremely low gestational age (22-28 weeks) infants develop LOS and 21% of very low birth weight (VLBW) infants surviving beyond three days of life (DOL) will develop LOS.<sup>4</sup> Among these infants, meningitis occurs in 23% of bacteremic infants while 38% of infants with a pathogen isolated from the cerebrospinal fluid (CSF) may not have an organism isolated from blood.<sup>4</sup> These infections are usually serious, causing a prolonged hospital stay and increased risk of mortality.<sup>4</sup>

Some cases of LOS can be prevented through proper central line insertion and maintenance practices. These are addressed in the CDC's Healthcare Infection Control Practices Advisory Committee (CDC/HICPAC) <u>Guidelines for the Prevention of Introvascular Cotheter-Related Infections</u>, 2011,<sup>2</sup> However, in a quality improvement study, almost one-third of LOS events were not related to central-lines.<sup>3</sup> Prevention strategies for these non-central line -related infection events have yet to be fully defined, but include adherence to hand-hygiene, parent and visitor education, and optimum nursery design features.<sup>4</sup> Other areas that likely influence the development of LOS include early enteral nutritional support and skin care practices.<sup>4</sup>

NOTE: Tracking LOS and MEN events does not exclude facilities from reporting other events that are part of their monthly reporting plan (MRP). This includes BSI surveillance in eligible NICU locations.

1

**∦**≡

## **Neonatal Component Training**

h

### Neonatal Component Training

### Self-paced Training

LOS/MEN Event Overview [CBT - 30 min]

**Audience**: All Beginner and Intermediate users of the Late-Onset Sepsis/Meningitis (LOS/MEN)

**Description**: This training will include a complete introduction to the NHSN Late-Onset Sepsis/Meningitis (LOS/MEN) Module, provide an overview of criteria for LOS/MEN, the analysis that will be performed, and the electronic capture of the data elements to meet criteria.

### Training Videos

Late Onset Sepsis & Meningitis Module (LOS/MEN) Overview – September 2021

- YouTube Link [Video 42 min]
- <u>Slideset</u> 📙 [PDF 3 MB]

### https://www.cdc.gov/nhsn/training/neonatal/index.html

## **NHSN Organism List**

### Supporting Materials

NHSN Patient Safety Component Alerts [PDF – 1 MB]

Unusual Susceptibility Profiles Alert – January 2022 P [PDF – 500 KB]

NHSN Organism List (All Organisms, Common Commensals, MBI Organisms, and UTI Bacteria) – January 2022

### To be used starting January 2022

#### **Change Summary Notes:**

There are no orgamism changes for the 2022 NHSN reporting year.

The following updates have been made to the document to assist with usabilty:

• A "Combined" tab has been added that includes a column labeled "NHSN Organism Category".

• The "NHSN Organism Category" column denotes how the organism can be used for NHSN reporting. The legend for the organism cateogies is below.

#### Legend:

 $\ensuremath{\textbf{ALL}}\xspace$  - Full list of organisms available within the NHSN application

**CC** - Organisms categorized as Common Commensals

MBI - Organisms categorized for Mucosal Barrier Injury

UTI - Organisms categorized for Urinary Tract Infection

#### Please refer to the appropriate protocol for details related to organisms from each category.



### What Facilities Need to Know about this Module

- No manual data entry available for this module: You will need an electronic process/system to upload your data
  - Software vendor
  - Electronic Health Record System
  - Homegrown System
- If BSI <u>and</u> LOS/MEN are part of your monthly reporting plan, <u>you must</u> <u>report both events</u>. A BSI cannot be deemed secondary to an LOS/MEN event.

## **LOS/MEN Module**

**Eligible Surveillance Locations** 

## Level II/III Nursery

- Mixed acuity nursery housing both Level II and level III neonates
- Level II special care nursery
  - Level I capabilities plus: Provide care for infants born ≥32 wks. gestation and weighing ≥1500 g who have
    physiologic immaturity or who are moderately ill with problems that are expected to resolve rapidly and are
    not anticipated to need subspecialty services on an urgent basis
  - Provide care for infants convalescing after intensive care
  - Provide mechanical ventilation for brief duration (<24 h) or continuous positive airway pressure or both
  - Stabilize infants born before 32 wks. gestation and weighing less than 1500 g until transfer to a neonatal intensive care facility
- Level III
  - Level II capabilities plus: Provide sustained life support
  - Provide comprehensive care for infants born < 32 wks. gestation and weighing <1500 g and infants born at all gestational ages and birth weights with critical illness
  - Provide prompt and readily available access to a full range of pediatric medical subspecialists, pediatric surgical specialists, pediatric anesthesiologists, and pediatric ophthalmologists
  - Provide a full range of respiratory support that may include conventional and/or high-frequency ventilation and inhaled nitric oxide
  - Perform advanced imaging, with interpretation on an urgent basis, including computed tomography, MRI, and echocardiography

## **Level III Nursery**

- Level II capabilities plus: Provide sustained life support
- Provide comprehensive care for infants born < 32 wks. gestation and weighing <1500 g and infants born at all gestational ages and birth weights with critical illness
- Provide prompt and readily available access to a full range of pediatric medical subspecialists, pediatric surgical specialists, pediatric anesthesiologists, and pediatric ophthalmologists
- Provide a full range of respiratory support that may include conventional and/or high-frequency ventilation and inhaled nitric oxide
- Perform advanced imaging, with interpretation on an urgent basis, including computed tomography, MRI, and echocardiography

## **Level IV Nursery**

- Regional NICUs
- Level III capabilities plus:
  - Located within an institution with the capability to provide surgical repair of complex congenital or acquired conditions
  - Maintain a full range of pediatric medical subspecialists, pediatric surgical subspecialists, and pediatric subspecialists at the site
  - Facilitate transport and provide outreach education

## **LOS/MEN Module**

Key Terms

## **Key Terms**

### Inborn Infant:

Any infant delivered at your facility

### Outborn Infant:

An infant born outside your facility

• Any infant that arrives at your facility in an ambulance is outborn

### Date of Event:

Collection date of the blood or CSF specimen from which an organism is identified by culture or non-culture based microbiologic testing, performed for purposes of clinical diagnosis or treatment.

## **Eligible Infant**

- Inpatient > 2 days,
- Housed on a Level II/III, Level III, or Level IV nursery
- Birth Weight 401 to 1500 grams
- Older than Day of Life (DOL) 3 but younger than DOL 121
  - Birth Date = DOL 1, regardless of the time of birth



## LOS/MEN Module

Key Concepts

## **Repeat Infection Timeframe (RIT)**

- 14-day timeframe during which no new infections of the same type, specifically, LOS or Meningitis, are reported for the same patient.
- Infant may have more than 1 episode of LOS/MEN during a single hospitalization

**BUT** there is a 14-day RIT during which no new infection of the same type can be reported

 An infant may have an LOS and MEN event during a RIT period since these are two different infections

### **Transfer Rule**

 If the date of the event occurs on the day of transfer to a receiving facility or the next day, the infection event will be identified by the receiving facility as present on admission (POA)

\*<u>Note:</u> Facilities will not be able to capture post discharge events

## **Transfer Rule Example**

Day of Life (DOL)	Event/Location Description
DOL 5	Infant in Facility A, NICU 1
DOL 6	Infant transferred from Facility A NICU 1 to Facility B NICU 1
DOL 7	LOS is present on admission (POA) to Facility B and no infection event will be attributed to Facility B or Facility A since electronic capture of laboratory results is not possible for the transferring facility.

## **LOS/MEN Module**

**Event Details** 

## Neonatal Laboratory-Confirmed Bloodstream Infection 1 (NLCBI 1)

An eligible infant has a recognized pathogen (specifically a bacterial or fungal organism which is not on the Common Commensals tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).

#### Table 3. Neonatal Laboratory-Confirmed Bloodstream Infection Criteria Criterion Neonatal Laboratory-Confirmed Bloodstream Infection (NLCBI) Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria. Must meet one of the following criteria: NLCBI 1 An eligible infant has a recognized pathogen (specifically a bacterial or fungal organism which is not on the Common Commensals tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). NLCBI 2 A Common Commensal (specifically, a bacterial organism which is on the Common Commensal tab of the NHSN Organisms List) is identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). AND

Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent\*(s) from the Table 6 LOS/MEN antimicrobial list and continued for 5 or more calendar days (referred to as 5 "qualifying antimicrobial days" or "QADs"). Days on which a new antimicrobial agent is administered count as QADs. Days between administrations of a new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations.

\* New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true:

- 1. Is listed in Table 6.
- The antimicrobial "start date", which is the date of antimicrobial initiation, must occur sometime within the LOS/MEN Window Period, which is 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date.
- Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent\*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations.
- Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period current start date. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period.)

Substitution of a different antimicrobial agent from Table 6 within the LOS/MEN Window Period due to therapy/organism sensitivity factors will continue to meet the requirements for QADs.

### LOS/MEN Protocol, page 9

## Neonatal Laboratory-Confirmed Bloodstream Infection 2 (NLCBI 2)

A Common Commensal (specifically, a bacterial organism which is on the NHSN Common Commensal list) is identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).

### AND

Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more **new** intravenous (IV) antimicrobial agent\*(s) from the Table 6 LOS/MEN antimicrobial list and continued for 5 or more calendar days (referred to as 5 "qualifying antimicrobial days" or "QADs").

### LOS/MEN Protocol, page 9

Criterion	Neonatal Laboratory-Confirmed Bloodstream Infection (NLCBI)							
	Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria.							
	Must meet one of the following criteria:							
NLCBI 1	An eligible infant has a recognized pathogen (specifically a bacterial or fungal organism which is not on the Common Commensals tab of the <u>NHSN Organisms List</u> ) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).							
	OR							
NLCBI 2	A Common Commensal (specifically, a bacterial organism which is on the Common Commensal tab of the <u>NHSN Organisms List</u> ) is identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).							
	Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more <b>new</b> intravenous (IV) antimicrobial agent*(s) from the Table 6 LOS/MEN antimicrobial list and continued for 5 or more calendar days (referred to as 5 "qualifying antimicrobial days" or "QADs"). Days on which a new antimicrobial agent is administered count as QADs. Days between administrations of a new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations.							
	<ul> <li>* New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true: <ol> <li>Is listed in Table 6.</li> <li>The antimicrobial "start date", which is the date of antimicrobial initiation, must occur sometime within the LOS/MEN Window Period, which is 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date.</li> <li>Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations.</li> <li>Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period current start date. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period.)</li> </ol> </li> </ul>							

## **LOS/MEN Window Period**

- The 5-day period around the common commensal positive blood or CSF specimen that includes the 2 days before, the day of, and the 2 days after the LOS/MEN event date. Exception: LOS/MEN period may be shortened in cases when the LOS/MEN date of event occurs on DOL 4 or 5. Example cases are as follows:
  - Example: LOS/MEN date of event, DOL 4: LOS/MEN Window Period = 3 days, the day of the LOS/MEN date of event and the 2 days after. Rationale: The 2 days before LOS/MEN event date are before DOL 4 and the infant is not eligible for surveillance on those days.
  - Example: LOS/MEN date of event, DOL 5: LOS/MEN Window Period = 4 days, the 1 day before the LOS/MEN date of event (DOL 4), LOS/MEN event date and 2 days after.

# Eligible Antimicrobials for NLCBI 2 and NLCM 2 Events (Table 6)

Table 6. List of Intravenous Antimicrobials Eligible to Cite an NLCBI 2 or NLCM

Table 0. List of fillave
2 Event
Ampicillin
Ampicillin-Sulbactam
Cefazolin
Cefepime
Cefotaxime
Ceftazidime
Ceftriaxone
Clindamycin
Gentamicin
Imipenem
Linezolid
Meropenem
Metronidazole
Nafcillin
Oxacillin
Penicillin G
Piperacillin-Tazobactam
Vancomycin

LOS/MEN Protocol, page 14

## **New Antimicrobial Agent**

Must meet all four criteria



- 1. Listed in Table 6 of the LOS/MEN protocol
- 2. The agent must be administered intravenously (IV)
- 3. The antimicrobial agent must be started on or after DOL 4 AND within 2 days before or 2 days after the collection date of the positive blood or CSF specimen
- 4. Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period

## What Are Qualifying Antimicrobial Days (QADs)?

- QADs are days on which a new antimicrobial agent is administered
- One or more new antimicrobial agents must be continued for at least 5 calendar days
  - Days between administrations of a new antimicrobial agent also count as long as there is no more than 1 calendar day gap between administration
  - The 5-calendar day requirement can be met with multiple antimicrobial agents, as long as each antimicrobial agent was determined to be new

## **Determining QADs – Example**

Date	DOL	Antimicrobial Administered	Positive Specimen Collection	
Infant E				
June 12	11			
June 13	12			
June 14	13	Ampicillin		
June 15 14 QAD/s		Ampicillin	(+) Blood culture for Staphylococcus capitis	
June 16	15	Ampicillin		
June 17	16	Vancomycin		
June 18	17	Vancomycin		

Explanation: Since Ampicillin was not given in the 2 days preceding the first antimicrobial initiated during the LOS/MEN Window Period (denoted by the shaded area) and was started within the LOS/MEN Window Period, Ampicillin is a new antimicrobial agent. The change to Vancomycin within the LOS/MEN window can be used to meet the ≥ 5-day QAD requirement and an NLCBI 2 event is identified.



**Note:** LOS/MEN Window Period in grey.

## Neonatal Laboratory-Confirmed Meningitis 1 (NLCM 1)

An NHSN recognized pathogen, which is not an NHSN common commensal, identified from a cerebrospinal fluid (CSF) specimen obtained from an infant and tested by a culture or non-culture based microbiological testing method, performed for purposes of clinical diagnosis or treatment (not for purposes of active surveillance)

### LOS/MEN Protocol, page 10

	Neonatal Laboratory-Confirmed Meningitis (NLCM)						
	Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria.						
NLCM 1	An eligible infant has a recognized pathogen (specifically, a bacterial or fungal organism which is not on the Common Commensal tab of the <u>NHSN Organisms List</u> ) identified from a CSF specimen by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).						
	OR						
NLCM 2	A Common Commensal is identified from a CSF specimen (specifically, a bacterial organism which is on the Common Commensal tab of the <u>NHSN Organisms List</u> ) from one or more CSF specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).						
	AND						
	Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more <b>new</b> intravenous (IV) antimicrobial agent*(s) from Table 6 LOS/MEN antimicrobial list that are continued for 5 or more calendar days (referred to as 5 "qualifying antimicrobial days" or "QADs"). Days on which a new antimicrobial agent is administered count as QADs. Days between administrations of a new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations.						
	* New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true:						
	<ol> <li>Is listed in Table 6.</li> <li>The antimicrobial "start date", which is the date of antimicrobial initiation, must occur sometime within the LOS/MEN Window Period which includes 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date.</li> </ol>						
	3. Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations.						
	<ol> <li>Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period.)</li> </ol>						
	Period.) Substitution of a different antimicrobial agent from Table 6 within the LOS/MEN Window						

## Neonatal Laboratory-Confirmed Meningitis 2 (NLCM 2)

An NHSN Common Commensal is identified from a CSF obtained from an infant and tested by a culture or specimen non-culture based microbiological testing method, performed for purposes of clinical diagnosis or treatment

### AND

Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent\*(s) from Table 6 LOS/MEN antimicrobial list that are continued for 5 or more calendar days (referred to as 5 "qualifying antimicrobial

days" or "QADs").

## 'QADs").

#### Table 4. Neonatal Laboratory-Confirmed Meningitis Criteria Criterion Neonatal Laboratory-Confirmed Meningitis (NLCM) Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria. Must meet one of the following criteria: NLCM 1 An eligible infant has a recognized pathogen (specifically, a bacterial or fungal organism which is not on the Common Commensal tab of the NHSN Organisms List) identified from a CSF specimen by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). OR NLCM 2 A Common Commensal is identified from a CSF specimen (specifically, a bacterial organism which is on the Common Commensal tab of the NHSN Organisms List) from one or more CSF specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). AND Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent\*(s) from Table 6 LOS/MEN antimicrobial list that are continued for 5 or more calendar days (referred to as 5 "qualifying antimicrobial days" or "QADs"). Days on which a new antimicrobial agent is administered count as QADs. Days between administrations of a new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations \* New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true: Is listed in Table 6. The antimicrobial "start date", which is the date of antimicrobial initiation. must occur sometime within the LOS/MEN Window Period which includes 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date. Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent\*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations. 4. Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period.) Substitution of a different antimicrobial agent from Table 6 within the LOS/MEN Window Period due to therapy/organism sensitivity factors will continue to meet the requirements for QADs.

LOS/MEN Protocol, page 10

## **Reporting Instructions**

- If both NLCBI and NLCM are met, both should be reported with the event date reported as the date(s) of specimen collection
- If an NLCBI 1 and NLCBI 2 are identified from a specimen, the event should be reported as NLCBI 1 with the "recognized pathogen" reported as pathogen 1 and the common commensal as pathogen 2
- An NLCM 1 shall be reported if both NLCM 1 and NLCM 2 events are both identified from the same specimen
- Active surveillance cultures are not eligible for NLCBI or NLCM criteria

## **Data Collection and Reporting**

## **The LOS/MEN Calculator**

- Uses computer algorithms to identify Late-Onset Sepsis and Meningitis Events and denominator eligible infants (numerator and denominator, respectively)
- Software library that can be integrated into your system
- On-premise deployment: can be invoked locally

## **Data Collection and Reporting**


- The LOS/MEN surveillance protocol is designed to enable use of computerbased algorithms applied to electronic healthcare data sources to identify infants who qualify for the LOS/MEN numerator and denominator
- LOS/MEN numerator and denominator data must be submitted to NHSN electronically. <u>Reporting manually, using NHSN's web interface, is not an</u> <u>option</u>
- Healthcare facilities must report LOS/MEN data to NHSN via an electronic data standard known as Clinical Document Architecture (CDA)

## Monthly Reporting Plans (MRPs)

andatory fields marked with *		
	) *: Jeff Aycock	ACH (ID 14596)
	n *: March r *: 2021	
		N Neonatal Component Modules Followed this month
Location	LOS/MEN	
NICU II - LEVEL 2 NICU	×	
NICU III - LEVEL 3 NICU	$\checkmark$	
NICU IV - LEVEL 4 NICU	~	

- Used by all NHSN facilities to inform CDC which NICU location will be used in a given month.
- Participating facilities must select the location used, if any, the events that will be monitored in that month.
- MRPs are manually completed in the application.

## **Adding a Monthly Reporting Plan**



- Select month/year, location and events if you are following LOS/MEN module for that month/year
- Select the option 'No' only if you are not following LOS/MEN module for a given month/year

## **Reporting Guidance**

- You will be responsible for uploading events and denominator data via CDA on a monthly basis
  - Deadline: 1 month from the last date of the month
    - Example: September data, due October 31<sup>st</sup>.
- You can send the numerator and denominator data in the same file.
  - When submitting separate numerator and denominator files, Upload the denominator first, then numerator.

## **Data Validation**

## **Initial Validation – Synthetic Data Set**

- We encourage all participating facilities to utilize our synthetic data set and the corresponding test cases to validate software capture of numerator and denominator data.
  - Process where "fake" data is processed through the software vendor system to ensure accurate identification of numerator events and denominator data.
    - Answer key and test plan provided as resources for selfevaluation
    - Available to Software Vendors upon request via email

## **Event Validation -**

- Before uploading monthly events, we encourage review of an eligible location's event line listing.
- If there is a returned event, you must correct the error and reupload the events via CDA.

							xample
LOS/MEN Events - July 2021							AN
Patient ID	Last Name	First Name	Location	Event Date	Event Type	Organism(s)	
908456	Williams	Mila	NICU 1	7/30/2021	NLCBI 1	MRSA	
124765	Jones	Jared	NICU 1	7/22/2021	NLCBI 2	Streptococcus viridans	
125786	Davis	Michelle	NICU 1	7/14/2021	NLCM 2	Coagulase-negative staphylococcus	

# If You Are Planning to Track and Report LOS/MEN Events...

- Please contact <u>NHSN@cdc.gov</u>. Subject Line: LOS/MEN Implementation, Attention: LaTasha Boswell
  - We'd like to support your facility during the development and implementation process!

## **Summary**

- Neonatal Component and Late-Onset Sepsis/Meningitis Event (LOS/MEN) resources are available on the NHSN website
- LOS have two event types: NLCBI 1 and NLCBI 2
- MEN has two event types: NLCM 1 and NLCM 2
- There is no manual entry of LOS/MEN numerator or denominator data. All event and denominator data are uploaded via CDA
- NHSN recommends the use of the Synthetic Data Set for initial validation



## Thank you!

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

